Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

In 30 pa­tients with a num­ber of au­toim­mune con­di­tions who re­ceived Kyver­na Ther­a­peu­tics’ CAR-T cell ther­a­py, 21 were able to stop tak­ing their im­mune dis­ease …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.